<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
Blogs

Pharmacy News and Stories

Patient Care

Research    Patient Care    Faculty    Pharmacy

Jeffres Publishes in JAMA Surgery Journal

New research from Dr. Meghan Jeffres, PharmD, Skaggs School of Pharmacy and Pharmaceutical Sciences, Massachusetts General Hospital (MGH), and University of Porto in Portugal, indicates that most surgical patients with a history of penicillin allergy can safely be given the guideline-recommended antibiotic cefazolin to prevent infection instead of alternative antibiotics that are less effective and more expensive. The researchers reported in JAMA Surgery that the frequency of allergies to both penicillins and cefazolin was so small that most patients should receive cefazolin regardless of their allergy history.


Author SOP Communications | Publish Date March 16, 2021
Full Story

School of Pharmacy In the News

NewsMedical

Study highlights importance of positive and negative selection in evolution of SARS-CoV-2 variants

news outletNewsMedical
Publish DateDecember 28, 2021

Krishna Mallela, PhD, and his team received press coverage for the lab’s work on SARS-CoV-2 variants, which focused on the study which highlights the importance of positive and negative selection in evolution of SARS-CoV-2 variants.

Full Story
Health.com

How the 2 New Pills for Treating COVID-19 Stack Up: Here's What Experts Say

news outletHealth.com
Publish DateDecember 28, 2021

Both Pfizer’s Paxlovid and Merck’s molnupiravir are cleared for emergency use in non-hospitalized people who have mild-to-moderate symptoms and are at heightened risk of developing severe disease. Peter Anderson, PharmD spoke with Health regarding their effectiveness.

Full Story
The Guardian

Covid pills are ‘very promising’ – but what are the challenges in using them?

news outletThe Guardian
Publish DateDecember 28, 2021

Peter Anderson, PharmD spoke with the Guardian about Paxlovid and molnupiravir, which were authorized by the FDA recently. Supplies of Paxlovid are limited while molnupiravir is less effective than hoped, but they are a very important step forward.

Full Story
Vanguard

US, NGO combat cancer, train 34 Nigerian oncology pharmacists

news outletVanguard
Publish DateDecember 14, 2021

Cindy O’Bryant, PharmD, had her recent Fulbright-sponsored work in Nigeria featured in a Vanguard article. The story examines the work being done to help reduce the high incidence of cancer, tackle late detection and improve general outlook of cancer in Nigeria.

Full Story